Valuation: Acura Pharmaceuticals, Inc.

Market Cap 32.79L 29.22L 26.79L 24.35L 45.77L 31Cr 46.82L 3.2Cr 1.28Cr 16Cr 1.23Cr 1.2Cr 52Cr P/E 2020
-5.25x
P/E 2021 -25x
Enterprise Value 34.14L 30.42L 27.9L 25.35L 47.66L 32Cr 48.75L 3.33Cr 1.34Cr 17Cr 1.28Cr 1.25Cr 54Cr EV / Sales 2020
2.91x
EV / Sales 2021 20.9x
Free-Float
98.31%
Yield 2020 *
-
Yield 2021 -
1 day+50.00%
1 week+50.00%
Current month+50.00%
1 month+197.03%
3 months+200.00%
6 months-40.00%
Current year-40.00%
1 week 0
Extreme 0.0003
0
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 1.0E-6
0.01
1 year 0
Extreme 1.0E-6
0.01
3 years 0
Extreme 1.0E-6
0.75
5 years 0
Extreme 1.0E-6
0.75
10 years 0
Extreme 0
1.4
Manager TitleAgeSince
Chief Executive Officer 67 01/04/2011
Director of Finance/CFO 73 01/02/1998
Director of Finance/CFO 62 01/08/2024
Director TitleAgeSince
Chairman 75 01/10/1996
Director/Board Member 55 01/12/2002
Director/Board Member 83 01/03/1998
Date Insider Type Main position Quantity % Market Cap. Importance
02/01/26 Exercice

Director

1,50,000 0.2273%
02/01/26 Exercice

Director

1,50,000 0.2273%
02/01/26 Exercice

Director

1,50,000 0.2273%
Change 5-day change 1-year change 3-year change Capi.($)
+50.00%+50.00%-40.00%+29,900.00% 19.99T
+10.00%+5.18%+54.35%+71.20% 6.06TCr
+1.44%+4.06%+22.70%+101.03% 5.55TCr
+3.32%+4.11%+14.82%+75.04% 5.52TCr
+0.46%-2.86%+23.34%+33.77% 4.33TCr
+6.42%+3.20%+21.14%+105.56% 4.04TCr
+2.82%+7.24%+236.59%+801.17% 4.16TCr
-3.79%+19.39%+91.90%+77.13% 3.33TCr
+5.32%+6.04%+20.27%+52.98% 3.23TCr
+5.32%+15.84%-40.93%+342.66% 2.29TCr
Average +8.16%+9.52%+40.42%+3,156.05% 3.85TCr
Weighted average by Cap. +3.76%+4.06%+51.58%+169.52%

Financials

2020 2021
Net sales 35.7L 31.81L 29.17L 26.51L 49.84L 34Cr 50.98L 3.49Cr 1.4Cr 18Cr 1.34Cr 1.31Cr 57Cr 15.63L 13.93L 12.77L 11.61L 21.82L 15Cr 22.32L 1.53Cr 61.2L 7.82Cr 58.67L 57.41L 25Cr
Net income -12.08L -10.76L -10L -9L -16.87L -11Cr -17.25L -1.18Cr -47.3L -6.04Cr -45.34L -44.37L -19Cr -9L -8L -7L -7L -12.27L -8.31Cr -12.55L -85.85L -34.42L -4.4Cr -32.99L -32.29L -14Cr
Net Debt 58.56L 52.18L 47.86L 43.49L 81.76L 55Cr 83.62L 5.72Cr 2.29Cr 29Cr 2.2Cr 2.15Cr 93Cr 1L 1L 1L 1L 2L 1.28Cr 2L 13.19L 5L 67.53L 5L 5L 2.14Cr
Logo Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Employees
-
Date Price Change Volume
03/26/03 $0.000300 +50.00% 200
  1. Stock Market
  2. Stocks
  3. ACUR Stock